title: Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL).
authors.affiliation: Department of Haematology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK.
authors.forename: Adrian
authors.initials: A
authors.lastname: Bloor
authors.forename: Erwin
authors.initials: E
authors.lastname: De Cock
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Hatswell
authors.forename: Radek
authors.initials: R
authors.lastname: Wasiak
authors.forename: Jamie
authors.initials: J
authors.lastname: Elvidge
authors.forename: Ceilidh
authors.initials: C
authors.lastname: Stapelkamp
authors.forename: Tsveta
authors.initials: T
authors.lastname: Hadjivassileva
authors.forename: Amin
authors.initials: A
authors.lastname: Haiderali
authors.forename: Julio
authors.initials: J
authors.lastname: Delgado
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D016896:Treatment Outcome
keywords: alemtuzumab; chronic lymphocytic leukaemia; fludarabine; refractory; therapy costs